Atlas Trials

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Clinical trial NCT02889900 · COMPLETED

Trial details

NCT number
NCT02889900
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Platinum Resistant Ovarian Cancer
Start date
2017-01-17
Primary completion
2019-08-27
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.